drugset / Trial / NCT01601002
LEPR Polymorphism Weight Gain by Mirtazapine in Late Life Depression
Phase 4
Completed
19 enrolled
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
NaSingle-groupOpen-label
Summary
Patients with an episode of depression in late life prescribed mirtazapine recruited from a clinical sample will be monitored for weight and receive a blood test during their usual course of treatment to determine polymorphisms in a specific gene (LEPR) thought to affect weight gain.
Timeline
- Start
- 2012-06
- Primary completion
- 2015-10
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirtazapine | Other / unclassified | 7.5 mg | — |
| Subject | Mirtazapine | Other / unclassified | 45 mg | — |